Lexeo prices $135M offering; FDA open to faster LX2006 approval path

Lexeo Therapeutics, Inc.

Priced public offering of 15.625M shares at $8.00 and $10M private placement (pre-funded warrants) to Balyasny; gross proceeds ~$135M.
Preliminary cash, cash equivalents and investments of $122.8M as of Sept 30, 2025.
FDA indicated openness to accelerated BLA for LX2006 using pooled Phase I/II and pivotal study data; enhanced manufacturing comparability required.
LX2006 interim data: sustained or deepening improvements in LVMI and frataxin in majority of 16 participants at >=6 months follow-up.
LX2020: 9 participants dosed; one Grade 3 SVT resolved; low-dose cohort shows stable cardiac parameters; more data expected Jan 2026.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.